Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Society of Nephrology. Clinical Journal

• Publication date

  2010-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2215/CJN.08111109PMID 20056761PMCID PMC2827577
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

  2010influential reference
• Rapid Development of Hypertension by Sorafenib: Toxicity or Target?

  2009cited by this paper
• Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

  2009cited by this paper
• Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

  2009cited by this paper
• Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors

  2009cited by this paper
• Reinforcing Feedback Loop of Renal Cyclic Guanosine 3′5′-Monophosphate and Interstitial Hydrostatic Pressure in Pressure-Natriuresis

  2009cited by this paper
• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

  2009cited by this paper
• A new equation to estimate glomerular filtration rate.

  2009cited by this paper
• Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

  2009cited by this paper
• Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.

  2009cited by this paper
• Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma

  2009cited by this paper
• Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736).

  2008cited by this paper
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

  2008cited by this paper
• Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

  2008cited by this paper
• Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

  2008cited by this paper
• VEGF Inhibition and Renal Thrombotic Microangiopathy

  2008cited by this paper
• VEGF inhibition and renal thrombotic microangiopathy.

  2008cited by this paper
• Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.

  2008cited by this paper
• VEGF inhibition and renal thrombotic microangiopathy.

  2008cited by this paper
• A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

  2008cited by this paper
• Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.

  2007cited by this paper
• Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.

  2006cited by this paper
• Effect of Nitric Oxide Synthase Inhibition on Proteinuria in Glomerular Immune Injury

  2006cited by this paper
• Mechanisms of hypertension associated with BAY 43-9006.

  2006cited by this paper
• AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

  2005cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• Production and Role of Extracellular Guanosine Cyclic 3′, 5′ Monophosphate in Sodium Uptake in Human Proximal Tubule Cells

  2004cited by this paper
• Angiogenic growth factors and hypertension

  2004cited by this paper
• Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

  2004cited by this paper
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• Cyclic GMP signaling in podocytes

  2002cited by this paper
• Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Use of single voided urine samples to estimate quantitative proteinuria.

  1983cited by this paper
• Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension.

  1972cited by this paper

• Morphometric and Molecular Interplay in Hypertension-Induced Cardiac Remodeling with an Emphasis on the Potential Therapeutic Implications

  2025cites this paper
• Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging

  2025cites this paper
• Glomerular pathology of vascular endothelial growth factor inhibition—A 12-year review at the Mayo Clinic

  2025cites this paper
• Study on the Mechanisms of Hypertension Induced by VEGFR Inhibitors during Antitumor Therapy

  2025cites this paper
• The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage

  2023cites this paper
• The Kidney in Normal Pregnancy and Preeclampsia

  2022cites this paper
• BLOOD PRESSURE INCREASES INDUCED BY IATROGENESIS, OVER THE COUNTER SUBSTANCES, AND HERBALS PRODUCTS

  2021cites this paper
• Onco-hypertension: An Emerging Specialty.

  2021cites this paper
• Onco-hypertension: Overview of hypertension with anti-cancer agents

  2021cites this paper
• A narrative review on the interaction between genes and the treatment of hypertension and breast cancer

  2021cites this paper
• Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.

  2021cites this paper
• Nintedanib-induced glomerular microangiopathy: a case report

  2020cites this paper
• Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma

  2020cites this paper
• CMAR_A_232823 91..102

  2020cites this paper
• Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases

  2019cites this paper
• Cardiovascular Disease and Cancer: Is There Increasing Overlap?

  2019cites this paper
• VEGF modulation and renal effects: Case report and review of the literature

  2019cites this paper
• Krebserkrankungen heilen und das Herz schützen

  2019cites this paper
• Hypertension and Antiangiogenesis

  2019cites this paper
• Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition

  2019cites this paper
• The effects of a hirudin/liposome complex on a diabetic nephropathy rat model

  2019cites this paper
• Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites

  2018cites this paper
• Comprehensive review of cardiovascular toxicity of drugs and related agents

  2018cites this paper
• RENAL INJURY IN PREECLAMPSIA: THE VIEW OF NEPHROLOGIST (LITERATURE REVIEW)

  2018cites this paper
• Tyrosine Kinase Inhibitor-Induced Hypertension

  2018cites this paper
• Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events

  2018influential citation
• Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors

  2018cites this paper
• Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

  2017cites this paper
• Neue Tumortherapien und Hypertonie

  2017influential citation
• Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition

  2017influential citation
• Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis

  2016cites this paper
• Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options

  2016cites this paper
• Cediranib in ovarian cancer: state of the art and future perspectives

  2016cites this paper
• Chapter 10 – Cardiovascular Complications from Cancer Therapy: Hypertension–Focus on Vascular Endothelial Growth Factor Inhibitors

  2016cites this paper
• Hypertension and renal toxicity during angiogenesis inhibition : Salt dependency and treatment options

  2016cites this paper
• Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors

  2016cites this paper
• Impaired Neovascularization and Reduced Capillary Supply in the Malignant vs. Non-malignant Course of Experimental Renovascular Hypertension

  2016cites this paper
• Hypertonie und renale thrombotische Mikroangiopathie unter anti-angiogener Tumortherapie

  2016cites this paper
• Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue

  2016cites this paper
• Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications

  2015cites this paper
• Renal cancer in kidney transplanted patients

  2015cites this paper
• A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors

  2015cites this paper
• Our own worst enemy: pharmacologic mechanisms of hypertension.

  2015cites this paper
• Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

  2015cites this paper
• Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension

  2015cites this paper
• Nephrotoxicity of Chemotherapy Agents

  2015cites this paper
• Biological Cancer Therapies and the Kidney

  2015cites this paper
• Chapter 16 – The Kidney in Normal Pregnancy and Preeclampsia

  2015cites this paper
• Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

  2014cites this paper
• Effects of obesity on vascular endothelial growth factor and erythropoietin in patients with arterial hypertension

  2014cites this paper
• Anti-VEGF Cancer Therapy in Nephrology Practice

  2014cites this paper
• Small Molecule Therapeutics Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non – Small Cell Lung Cancer

  2014cites this paper
• Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis

  2014cites this paper
• Discovery and Development of Antiangiogenetic Drugs in Ovarian Cancer

  2014cites this paper
• Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.

  2014cites this paper
• Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.

  2014cites this paper
• Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.

  2014cites this paper
• Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer

  2014cites this paper
• Emerging paradigms in cardiomyopathies associated with cancer therapies.

  2013cites this paper
• Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

  2013cites this paper
• Hipertensión maligna en pacientes tratados con inhibidores de crecimiento endotelial vascular

  2013cites this paper
• Malignant Hypertension in Patients Treated With Vascular Endothelial Growth Factor Inhibitors

  2013cites this paper
• Dasatinib-induced nephrotic-range proteinuria.

  2013cites this paper
• Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

  2013influential citation
• Onconephrology: the latest frontier in the war against kidney disease.

  2013cites this paper
• Cardiovascular toxicity of tyrosine kinase inhibitors

  2013cites this paper
• This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress

  2013cites this paper
• Nephrotoxicity of recent anti-cancer agents

  2013cites this paper
• Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1

  2013cites this paper
• Hypertension Grand Rounds Management of Antiangiogenic Therapy-Induced Hypertension

  2012cites this paper
• The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

  2012cites this paper
• Complications cardiaques et vasculaires des antiangiogéniques (à l’exception des effets rénaux et des complications hémorragiques)

  2012cites this paper
• Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

  2012cites this paper
• Gestión y Tratamiento de Residuos

  2012cites this paper
• Management of antiangiogenic therapy-induced hypertension.

  2012cites this paper
• Cediranib: a VEGF receptor tyrosine kinase inhibitor.

  2012cites this paper
• Early Response to Anti-Tumoral Treatment in Hepatocellular Carcinoma – Can Quantitative Contrast-Enhanced Ultrasound Predict Outcome?

  2012cites this paper
• Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.

  2011cites this paper
• Proteinuria and hypertension with tyrosine kinase inhibitors.

  2011cites this paper
• Hypertension Induced by VEGF Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker

  2011cites this paper
• Angiogenesis inhibitors for the treatment of ovarian cancer.

  2011cites this paper
• NEPHROTOXICITY OF ANTICANCER DRUGS – AN UNDERESTIMATED PROBLEM?

  2011cites this paper
• Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

  2011cites this paper
• Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.

  2010cites this paper
• Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?

  2010cites this paper
• Renal Involvement in Preeclampsia: Similarities to VEGF Ablation Therapy

  2010cites this paper
• Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors

  2010cites this paper
• Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients

  2010cites this paper
• The Kidney in Normal Pregnancy and Preeclampsia

  2009cites this paper
• Hypertension and renal disease during anti-cancer therapies

  year unknowncites this paper
• Nature Publishing Group Original Contributions Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1

  year unknowncites this paper